

# Perfalgan

10 mg/ml, solution for infusion

## Paracetamol



Read all of this leaflet carefully before you start using this medicine.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

**In this leaflet:**

1. What PERFALGAN 10 mg/ml, solution for infusion is and what it is used for
2. Before you use PERFALGAN 10 mg/ml, solution for infusion
3. How to use PERFALGAN 10 mg/ml, solution for infusion
4. Possible side effects
5. How to store PERFALGAN 10 mg/ml, solution for infusion
6. Further information

**1. WHAT PERFALGAN 10 mg/ml, solution for infusion IS AND WHAT IT IS USED FOR**

This medicine is an analgesic (it relieves pain) and an antipyretic (it lowers fever).  
The 100 ml vial or 100 ml bag is restricted to adults, adolescents and children weighing more than 33 kg.  
The 50 ml vial is restricted to term newborn infants, infants, toddlers and children weighing less than 33 kg.  
It is indicated for the short-term treatment of moderate pain, especially following surgery, and for the short-term treatment of fever.

**2. BEFORE YOU USE PERFALGAN 10 mg/ml, solution for infusion**

**Do not use PERFALGAN 10 mg/ml, solution for infusion**

- if you are allergic (hypersensitive) to paracetamol or to any of the other ingredients of Perfalgan
- if you are allergic (hypersensitive) to propacetamol (another analgesic for infusion and a precursor of paracetamol)
- if you suffer from a severe liver disease.

**Take special care with PERFALGAN 10 mg/ml, solution for infusion**

- use a suitable analgesic oral treatment as soon as this administration route is possible.
- if you suffer from a liver or kidney disease, or from alcohol abuse,
- if you are taking other medicines containing paracetamol,
- in cases of nutrition problems (malnutrition) or dehydration.

Inform your doctor before treatment if any of the above mentioned conditions apply to you.

**Taking or using other medicines**

Do not give anything else containing paracetamol while giving this medicine. This medicine contains paracetamol and this must be taken into account if other medicines containing paracetamol or propacetamol are taken, in order not to exceed the recommended daily dose (see following section). Inform your doctor if you are taking other medicines containing paracetamol or propacetamol as your doctor may need to change your dose.

A dose reduction should be considered for concomitant treatment with Probenecid.

Please inform your doctor or pharmacist if you are taking oral anticoagulants. Closer check-ups of the effect of the anticoagulant might be necessary.

Please inform your doctor or pharmacist if you are taking or have recently taken any other medicines, even those not prescribed.

**Pregnancy and breast-feeding**

**Pregnancy**

Inform your doctor if you are pregnant. PERFALGAN may be used during pregnancy. However, in this case the doctor must evaluate if the treatment is advisable.

Ask your doctor or pharmacist for advice before taking any medicine.

**Breast-feeding**

PERFALGAN may be used during breast-feeding.

Ask your doctor or pharmacist for advice before taking any medicine.

**Important information about some of the ingredients of PERFALGAN 10 mg/ml, solution for infusion**

This medicinal product contains less than 1 mmol sodium (23mg) per 100 ml of Perfalgan, i.e. essentially "sodium free".

**3. HOW TO USE PERFALGAN 10 mg/ml, solution for infusion**

You should not be given more medicine than the label says. Do not exceed the stated dose.

**Intravenous use.**

The 100 ml vial or 100 ml bag is restricted to adults, adolescents and children weighing more than 33 kg.

The 50 ml vial is restricted to term newborn infants, infants, toddlers and children weighing less than 33 kg.

**Dosage**

Dosing based on patient weight (please see the dosing table here below)

Patient weight	Dose per administration	Volume per administration	Maximum volume of Perfalgan (10 mg/mL) per administration based on upper weight limits of group (mL)***	Maximum Daily Dose **
≤10 kg*	7.5 mg/kg	0.75 mL/kg	7.5mL	30 mg/kg
> 10 kg to ≤33kg	15 mg/kg	1.5mL/kg	49.5mL	60mg/kg not exceeding 2g
> 33 kg to ≤50kg	15 mg/kg	1.5mL/kg	75 mL	60mg/kg not exceeding 3g
>50kg with additional risk factors for hepatotoxicity	1g	100mL	100mL	3g
> 50 kg and no additional risk factors for hepatotoxicity	1 g	100mL	100mL	4g

\* **Pre-term newborn infants:** No safety and efficacy data are available for pre-term newborn.

\*\* **Maximum daily dose:** The maximum daily dose as presented in the table above is for patients that are not receiving other paracetamol containing products and should be adjusted accordingly taking such products into account.

\*\*\***Patients weighing less will require smaller volumes.**

**The minimum interval between each administration must be at least 4 hours.**

**The minimum interval between each administration in patients with severe renal insufficiency must be at least 6 hours.**

**No more than 4 doses to be given in 24 hours.**

**The paracetamol solution is administered in intravenous infusion over 15 minutes.**

If you have the impression that the effect of PERFALGAN 10 mg/ml, solution for infusion is too strong or too weak, talk to your doctor.

**INFORMATION FOR HEALTH PROFESSIONALS**

Below is a summary of the dosage, dilution, administration and storage details for Perfalgan 10 mg/ml, solution for infusion. Reference should be made to the Summary of Product Characteristics for full prescribing information.

For the 50ml and 100ml vial, close monitoring is needed before the end of infusion.

**Dosage**

Dosing based on patient weight (please see the dosing table here below)

Patient weight	Dose per administration	Volume per administration	Maximum volume of Perfalgan (10 mg/mL) per administration based on upper weight limits of group (mL)***	Maximum Daily Dose **
≤10 kg*	7.5 mg/kg	0.75 mL/kg	7.5mL	30 mg/kg
> 10 kg to ≤33kg	15 mg/kg	1.5mL/kg	49.5mL	60mg/kg not exceeding 2g
> 33 kg to ≤50kg	15 mg/kg	1.5mL/kg	75 mL	60mg/kg not exceeding 3g
>50kg with additional risk factors for hepatotoxicity	1g	100mL	100mL	3g
> 50 kg and no additional risk factors for hepatotoxicity	1 g	100mL	100mL	4g

\* **Pre-term newborn infants:** No safety and efficacy data are available for pre-term newborn.

\*\* **Maximum daily dose:** The maximum daily dose as presented in the table above is for patients that are not receiving other paracetamol

FRONT

Country: <b>GB</b>	Bar-Code:	Execution Date	11	17-01-2014
		Draft N°	07	19-03-2013
Font Size/Leading	10 / 10	Tickness:	Artworks Status:	XX-XX
			Artworks Status:	XX-XX
Messageprint: 200x400 mm 135 x 75 mm	g/mq	Date:	Signature	MME
			Signature	MME
Product: <b>INS-PERFALGAN</b>	Die Cut	Materials:	PO Number:	
			PO Number:	
This artwork is Property of Bristol-Myers Squibb Anagni (FR)	FILM TAMPERING UNCLEAVED	Product Code:	8976A1	
			8976A1	
Die Cut	Materials:	Date	Draft N°:	11
			Draft N°:	11
P072	P347	Die Cut	Execution Date:	17-01-2014
			Execution Date:	17-01-2014
The proof colour could be different by true Pantone® reference				

P347	RETINO - SCREENED
	20%



**If you or your child use more PERFALGAN 10mg/ml, solution for infusion than if you or your child use should, talk to a doctor at once if you or your child take too much of this medicine even if you or your child seem feel well. This is because too much paracetamol can cause delayed, serious liver damage.**

In overdose cases, symptoms generally appear within the first 24 hours and comprise: nausea, vomiting, anorexia, pallor, abdominal pain and a risk of liver injury.

If you have any further questions on the use of this product ask your doctor or pharmacist.

**Reporting of side effects**

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.

**Ireland**

Pharmacovigilance Section  
Irish Medicines Board  
Kevin O'Malley House  
Earlsfort Centre  
Earlsfort Terrace  
IRL - Dublin 2  
Tel: +353 1 6764971 - Fax: +353 1 6762517  
Website: www.imb.ie  
e-mail: imbpharmacovigilance@imb.ie

**United Kingdom**

Yellow Card Scheme  
Website: www.mhra.gov.uk/yellowcar

**4. POSSIBLE SIDE EFFECTS**

Like all medicines, PERFALGAN 10 mg/ml, solution for infusion can cause side effects, although not everybody gets them.

- In very rare cases (less than 1 out of 10,000 persons, including isolated reports), a serious skin rash or allergic reaction may occur. **Stop the treatment** immediately and inform your doctor.
- In rare cases (more than 1 out of 10,000 persons and less than 1 out of 1,000 persons), the following may occur : a malaise, a drop in blood pressure or changes in laboratory test results : abnormally high levels of hepatic enzymes found during blood checks. Should this occur, inform your doctor as regular blood checks may be required later.
- In isolated cases, other changes in laboratory test results have been observed which have necessitated regular blood checks : abnormally low levels of some types of blood cells (platelets, white cells), possibly leading to bleeding from the nose or gums. Should this occur, inform your doctor.
  - Cases of redness of the skin, flushing, itching and abnormally rapid beating of the heart have been reported.
  - Cases of pain and burning sensation at injection site have been reported.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

**5. HOW TO STORE PERFALGAN 10 mg/ml, solution for infusion**

Keep out of the reach and sight of children.

Do not use PERFALGAN 10 mg/ml, solution for infusion after the expiry date which is stated on the packaging after EXP.

The expiry date refers to the last day of that month.

Do not store above 30°C. Do not refrigerate or freeze.

For the 100 ml bag, keep the immediate packaging in the outer, aluminium over-packaging.

For the 50ml vial, after dilution in 0.9% sodium chloride or 5% glucose : do not store for more than 1 hour (infusion time included).

Before administration, the product should be inspected visually. Do not use PERFALGAN if you notice any particulate matter and discoloration. For the 100ml bag, note that there is a potential presence of moisture between the bag and the outer sachet due to the sterilization process, the quality of the product is not impacted.

For single use only. The product should be used immediately after opening. Any unused solution should be discarded.

**6. FURTHER INFORMATION**

**What PERFALGAN 10 mg/ml, solution for infusion contains**

- The active substance is paracetamol. One ml contains 10 mg paracetamol.
- The other ingredients are mannitol, cysteine hydrochloride monohydrate, disodium phosphate dihydrate, sodium hydroxide, hydrochloric acid, water for injections.

**What PERFALGAN 10 mg/ml, solution for infusion looks like and contents of the pack**

Vials of 50 ml and 100 ml

Bags of 100 ml.

PERFALGAN 10 mg/ml solution for infusion is a clear and slightly yellowish solution.

PERFALGAN 10 mg/ml solution for infusion vials are supplied in packs of 12 vials.

PERFALGAN 10 mg/ml solution for infusion bags are supplied in cartons of 50 bags.

Not all pack sizes or presentation may be marketed.

**Marketing Authorisation Holder**

Bristol-Myers Squibb Pharmaceuticals Ltd  
BMS House  
Uxbridge Business Park  
Sanderson Road  
Uxbridge  
Middlesex UB8 1DH  
United Kingdom  
Manufacturer  
BRISTOL MYERS SQUIBB  
304, avenue du Docteur Jean Bru  
47000 AGEN, France  
or  
BRISTOL MYERS SQUIBB  
Loc. Fontana del Ceraso  
Anagni, Italy  
or  
Laboratoire RENAUDIN  
Z.A. Errobi  
64250 ITXASSOU, France  
or  
BIEFFE MEDITAL S.p.A.  
Via Nuova Provinciale, nc  
23034 GROSOTTO-SO, Italy  
or  
LABORATORIOS GRIFOLS, S.A.  
Passeig Fluvial, 24  
Poligono Industrial Autopista  
08150 Parets del Vallès  
BARCELONA  
(Spain)

For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.

**This leaflet was last revised in January 2014.**

containing products and should be adjusted accordingly taking such products into account.

**\*\*\*Patients weighing less will require smaller volumes.**

**The minimum interval between each administration must be at least 4 hours.**

**The minimum interval between each administration in patients with severe renal insufficiency must be at least 6 hours.**

**No more than 4 doses to be given in 24 hours.**

**Method of administration**

**RISK OF MEDICATION ERRORS**  
**Take care to avoid dosing errors due to confusion between milligram (mg) and milliliter (mL), which could result in accidental overdose and death.**

The paracetamol solution is administered in intravenous infusion over 15 minutes.

Patients weighing ≤ 10 kg:

- The glass vial/bag of Perfalgan should not be hung as an infusion due to the small volume of the medicinal product to be administered in this population.
- The volume to be administered should be withdrawn from the vial/bag and diluted in a 0.9% sodium chloride solution or 5% glucose solution up to one tenth (one volume Perfalgan into nine volumes diluent) and administered over 15 minute.
  - A 5 or 10 ml syringe should be used to measure the dose as appropriate for the weight of the child and the desired volume. However, this should never exceed 7.5ml per dose
  - The user should be referred to the product information for dosing guidelines.

For the 50ml and 100ml vials, a 0.8 mm needle (21 gauge needle) has to be used and the stopper vertically perforated at the spot specifically indicated.

It can also be diluted in 0.9% sodium chloride or 5% glucose up to one tenth (one volume Perfalgan into nine volumes diluent).

The diluted solution should be visually inspected and must not be used if opalescence, visible particulate matter or precipitate are found.



**BACK**

Country: <b>GB</b>	Bar-Code:	Execution Date	
		Draft N°	11 17-01-2014
Font Size/Leading	10 / 10	Thickness:	Artworks Status: <b>XX-XX</b>
			Artworks Status: <b>MME</b>
Message/Unit: <b>200x400 mm</b>	135 x 75 mm	g/mq	Date:
			Signature
Product: <b>INS-PERFALGAN</b>	Die Cut	Materials:	PO Number:
			Date
This artwork is Property of <b>Bristol-Myers Squibb Anagni (FR)</b>	FILM TAMPERING UNLEAVED	Product Code: <b>8976A1</b>	Draft N°: <b>11</b>
			Execution Date: <b>17-01-2014</b>
P072	P347	Die Cut	Film Quality Control
			The proof colour could be different by true Pantone® reference

